A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Clinical trial NCT06942572 · RECRUITING

Trial details

NCT number: NCT06942572
Sponsor: Splice Bio
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stargardt Disease Stargardt Macular Degeneration Stargardt Macular Dystrophy

Start date: 2025-02-11
Primary completion: 2028-10-31
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.